Back to News
Market Impact: 0.4
Lilly's EloraTZP Delivers Weight Loss Results In Phase 2b Trial
Source: Nasdaq
Healthcare & Biotech
Eli Lilly said its investigational EloraTZP combination of eloralintide and tirzepatide produced substantial weight loss and reductions in blood-sugar levels in a Phase 2b trial. The study enrolled 367 adults with obesity or overweight, supporting the clinical potential of Lilly's obesity and metabolic-disease pipeline.
AllMind Terminal
AI-powered research, real-time alerts, and portfolio analytics for institutional investors.
Request TrialMarket Sentiment
Overall Sentiment
moderately positive
Sentiment Score
0.60
Ticker Sentiment
LLY0.72
More News
- Eli Lilly says closely watched combo obesity regimen boosts weight loss in mid-stage trial
- Lilly’s Foundayo shows cardiovascular safety in diabetes trial
- Nvidia is approaching a breakout level. Plus, what we want to see from Micron
- Wall Street is closing out a strong quarter. Plus, Lilly's mixed obesity drug trial data
- Adding Lilly’s new drug to Zepbound helped people lose up to 23% of their weight. But there were more side effects.
- Lilly's oral GLP-1, Foundayo (orforglipron), demonstrated cardiovascular safety alongside sustained A1C reduction and weight loss in its largest and longest type 2 diabetes study
From AllMind Research
- Anthropic IPO Preview: Valuation, Timing, and What to Watch
- Shein After the IPO: Venue, Valuation, and What Must Be Proved
- What AI Research Tools Should a Small Hedge Fund Buy First?
- Research Workflows, Report Format Selection, and Interactive Synthesis
- Can ChatGPT Analyze a 10-K? A Verification Workflow